284 related articles for article (PubMed ID: 34649298)
1. T-cell immune response after mRNA SARS-CoV-2 vaccines is frequently detected also in the absence of seroconversion in patients with lymphoid malignancies.
Marasco V; Carniti C; Guidetti A; Farina L; Magni M; Miceli R; Calabretta L; Verderio P; Ljevar S; Serpenti F; Morelli D; Apolone G; Ippolito G; Agrati C; Corradini P
Br J Haematol; 2022 Feb; 196(3):548-558. PubMed ID: 34649298
[TBL] [Abstract][Full Text] [Related]
2. Single dose of BNT162b2 mRNA vaccine against severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) induces neutralising antibody and polyfunctional T-cell responses in patients with chronic myeloid leukaemia.
Harrington P; Doores KJ; Radia D; O'Reilly A; Lam HPJ; Seow J; Graham C; Lechmere T; McLornan D; Dillon R; Shanmugharaj Y; Espehana A; Woodley C; Saunders J; Curto-Garcia N; O'Sullivan J; Raj K; Kordasti S; Malim MH; Harrison C; de Lavallade H
Br J Haematol; 2021 Sep; 194(6):999-1006. PubMed ID: 34085278
[TBL] [Abstract][Full Text] [Related]
3. Immunogenicity and tolerability of COVID-19 messenger RNA vaccines in primary immunodeficiency patients with functional B-cell defects.
Pham MN; Murugesan K; Banaei N; Pinsky BA; Tang M; Hoyte E; Lewis DB; Gernez Y
J Allergy Clin Immunol; 2022 Mar; 149(3):907-911.e3. PubMed ID: 34952033
[TBL] [Abstract][Full Text] [Related]
4. Adaptive immunity and neutralizing antibodies against SARS-CoV-2 variants of concern following vaccination in patients with cancer: the CAPTURE study.
Fendler A; Shepherd STC; Au L; Wilkinson KA; Wu M; Byrne F; Cerrone M; Schmitt AM; Joharatnam-Hogan N; Shum B; Tippu Z; Rzeniewicz K; Boos LA; Harvey R; Carlyle E; Edmonds K; Del Rosario L; Sarker S; Lingard K; Mangwende M; Holt L; Ahmod H; Korteweg J; Foley T; Bazin J; Gordon W; Barber T; Emslie-Henry A; Xie W; Gerard CL; Deng D; Wall EC; Agua-Doce A; Namjou S; Caidan S; Gavrielides M; MacRae JI; Kelly G; Peat K; Kelly D; Murra A; Kelly K; O'Flaherty M; Dowdie L; Ash N; Gronthoud F; Shea RL; Gardner G; Murray D; Kinnaird F; Cui W; Pascual J; Rodney S; Mencel J; Curtis O; Stephenson C; Robinson A; Oza B; Farag S; Leslie I; Rogiers A; Iyengar S; Ethell M; Messiou C; Cunningham D; Chau I; Starling N; Turner N; Welsh L; van As N; Jones RL; Droney J; Banerjee S; Tatham KC; O'Brien M; Harrington K; Bhide S; Okines A; Reid A; Young K; Furness AJS; Pickering L; Swanton C; ; Gandhi S; Gamblin S; Bauer DLV; Kassiotis G; Kumar S; Yousaf N; Jhanji S; Nicholson E; Howell M; Walker S; Wilkinson RJ; Larkin J; Turajlic S;
Nat Cancer; 2021 Dec; 2(12):1305-1320. PubMed ID: 35121899
[TBL] [Abstract][Full Text] [Related]
5. Impaired seroconversion after SARS-CoV-2 mRNA vaccines in patients with solid tumours receiving anticancer treatment.
Amatu A; Pani A; Patelli G; Gagliardi OM; Loparco M; Piscazzi D; Cassingena A; Tosi F; Ghezzi S; Campisi D; Grifantini R; Abrignani S; Siena S; Scaglione F; Sartore-Bianchi A
Eur J Cancer; 2022 Mar; 163():16-25. PubMed ID: 35032813
[TBL] [Abstract][Full Text] [Related]
6. COVID-19 Vaccine Type and Humoral Immune Response in Patients Receiving Dialysis.
Garcia P; Anand S; Han J; Montez-Rath ME; Sun S; Shang T; Parsonnet J; Chertow GM; Schiller B; Abra G
J Am Soc Nephrol; 2022 Jan; 33(1):33-37. PubMed ID: 34645698
[No Abstract] [Full Text] [Related]
7. Antibody Responses after SARS-CoV-2 Vaccination in Patients with Liver Diseases.
Bakasis AD; Bitzogli K; Mouziouras D; Pouliakis A; Roumpoutsou M; Goules AV; Androutsakos T
Viruses; 2022 Jan; 14(2):. PubMed ID: 35215801
[TBL] [Abstract][Full Text] [Related]
8. Predictors of poor seroconversion and adverse events to SARS-CoV-2 mRNA BNT162b2 vaccine in cancer patients on active treatment.
Buttiron Webber T; Provinciali N; Musso M; Ugolini M; Boitano M; Clavarezza M; D'Amico M; Defferrari C; Gozza A; Briata IM; Magnani M; Paciolla F; Menghini N; Marcenaro E; De Palma R; Sacchi N; Innocenti L; Siri G; D'Ecclesiis O; Cevasco I; Gandini S; DeCensi A
Eur J Cancer; 2021 Dec; 159():105-112. PubMed ID: 34742157
[TBL] [Abstract][Full Text] [Related]
9. Humoral and cellular responses after a third dose of SARS-CoV-2 BNT162b2 vaccine in patients with lymphoid malignancies.
Re D; Seitz-Polski B; Brglez V; Carles M; Graça D; Benzaken S; Liguori S; Zahreddine K; Delforge M; Bailly-Maitre B; Verrière B; Chamorey E; Barrière J
Nat Commun; 2022 Feb; 13(1):864. PubMed ID: 35165284
[TBL] [Abstract][Full Text] [Related]
10. Heterologous ChAdOx1 nCoV-19 and BNT162b2 prime-boost vaccination elicits potent neutralizing antibody responses and T cell reactivity against prevalent SARS-CoV-2 variants.
Groß R; Zanoni M; Seidel A; Conzelmann C; Gilg A; Krnavek D; Erdemci-Evin S; Mayer B; Hoffmann M; Pöhlmann S; Liu W; Hahn BH; Beil A; Kroschel J; Jahrsdörfer B; Schrezenmeier H; Kirchhoff F; Münch J; Müller JA
EBioMedicine; 2022 Jan; 75():103761. PubMed ID: 34929493
[TBL] [Abstract][Full Text] [Related]
11. B- and T-Cell Responses After SARS-CoV-2 Vaccination in Patients With Multiple Sclerosis Receiving Disease Modifying Therapies: Immunological Patterns and Clinical Implications.
Iannetta M; Landi D; Cola G; Campogiani L; Malagnino V; Teti E; Coppola L; Di Lorenzo A; Fraboni D; Buccisano F; Grelli S; Mozzani M; Zingaropoli MA; Ciardi MR; Nisini R; Bernardini S; Andreoni M; Marfia GA; Sarmati L
Front Immunol; 2021; 12():796482. PubMed ID: 35111162
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of Antibody Response to SARS-CoV-2 mRNA-1273 Vaccination in Patients With Cancer in Florida.
Giuliano AR; Lancet JE; Pilon-Thomas S; Dong N; Jain AG; Tan E; Ball S; Tworoger SS; Siegel EM; Whiting J; Mo Q; Cubitt CL; Dukes CW; Hensel JA; Keenan RJ; Hwu P
JAMA Oncol; 2022 May; 8(5):748-754. PubMed ID: 35266953
[TBL] [Abstract][Full Text] [Related]
13. Immunogenicity of the BNT162b2 COVID-19 mRNA vaccine and early clinical outcomes in patients with haematological malignancies in Lithuania: a national prospective cohort study.
Maneikis K; Šablauskas K; Ringelevičiūtė U; Vaitekėnaitė V; Čekauskienė R; Kryžauskaitė L; Naumovas D; Banys V; Pečeliūnas V; Beinortas T; Griškevičius L
Lancet Haematol; 2021 Aug; 8(8):e583-e592. PubMed ID: 34224668
[TBL] [Abstract][Full Text] [Related]
14. Seroconversion and kinetic of anti SARS-COV-2 antibodies in 25 patients with hematological malignancies who recovered from SARS-COV-2 infection.
Candoni A; Pizzano U; Fabris M; Curcio F; Fanin R
Hematol Oncol; 2021 Aug; 39(3):428-431. PubMed ID: 33951220
[No Abstract] [Full Text] [Related]
15. Response to mRNA vaccination for COVID-19 among patients with multiple myeloma.
Stampfer SD; Goldwater MS; Jew S; Bujarski S; Regidor B; Daniely D; Chen H; Xu N; Li M; Green T; Fung E; Aquino E; Swift R; Eshaghian S; Preugschat K; Feinstein AJ; Spektor TM; Berenson JR
Leukemia; 2021 Dec; 35(12):3534-3541. PubMed ID: 34326466
[TBL] [Abstract][Full Text] [Related]
16. Kinetics of the Antibody Response to Boostering With Three Different Vaccines Against SARS-CoV-2.
Markewitz R; Juhl D; Pauli D; Görg S; Junker R; Rupp J; Engel S; Steinhagen K; Herbst V; Zapf D; Krüger C; Brockmann C; Leypoldt F; Dargvainiene J; Schomburg B; Sharifzadeh S; Nejad LS; Wandinger KP; Ziemann M
Front Immunol; 2022; 13():811020. PubMed ID: 35126395
[TBL] [Abstract][Full Text] [Related]
17. COVID-19 in vaccinated adult patients with hematological malignancies: preliminary results from EPICOVIDEHA.
Pagano L; Salmanton-García J; Marchesi F; López-García A; Lamure S; Itri F; Gomes-Silva M; Dragonetti G; Falces-Romero I; van Doesum J; Sili U; Labrador J; Calbacho M; Bilgin YM; Weinbergerová B; Serrano L; Ribera-Santa Susana JM; Malak S; Loureiro-Amigo J; Glenthøj A; Córdoba-Mascuñano R; Nunes-Rodrigues R; González-López TJ; Karlsson LK; Jiménez-Lorenzo MJ; Hernández-Rivas JÁ; Jaksic O; Ráčil Z; Busca A; Corradini P; Hoenigl M; Klimko N; Koehler P; Pagliuca A; Passamonti F; Cornely OA
Blood; 2022 Mar; 139(10):1588-1592. PubMed ID: 34748627
[TBL] [Abstract][Full Text] [Related]
18. Comparative Effectiveness and Antibody Responses to Moderna and Pfizer-BioNTech COVID-19 Vaccines among Hospitalized Veterans - Five Veterans Affairs Medical Centers, United States, February 1-September 30, 2021.
Bajema KL; Dahl RM; Evener SL; Prill MM; Rodriguez-Barradas MC; Marconi VC; Beenhouwer DO; Holodniy M; Lucero-Obusan C; Brown ST; Tremarelli M; Epperson M; Mills L; Park SH; Rivera-Dominguez G; Morones RG; Ahmadi-Izadi G; Deovic R; Mendoza C; Jeong C; Schrag SJ; Meites E; Hall AJ; Kobayashi M; McMorrow M; Verani JR; Thornburg NJ; Surie D; ; ;
MMWR Morb Mortal Wkly Rep; 2021 Dec; 70(49):1700-1705. PubMed ID: 34882654
[TBL] [Abstract][Full Text] [Related]
19. Humoral and T-cell immune response following three doses of SARS-CoV-2 mRNA vaccine in giant cell arteritis: analysis of a prospective cohort.
Bartoletti A; Fornara C; Delvino P; Franchi G; Ferrari A; Baldanti F; Montecucco C; Monti S
Clin Exp Rheumatol; 2024 Apr; 42(4):942. PubMed ID: 37812496
[No Abstract] [Full Text] [Related]
20. Safety and antibody response to two-dose SARS-CoV-2 messenger RNA vaccination in patients with multiple myeloma.
Greenberg RS; Ruddy JA; Boyarsky BJ; Werbel WA; Garonzik-Wang JM; Segev DL; Imus PH
BMC Cancer; 2021 Dec; 21(1):1354. PubMed ID: 34961488
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]